ABOUT US

we strive to develop patient-centered and
novel therapeutics with
cutting-edge science and technology

Who we are

Who we are

Simnova is a clinical stage biotech company focusing on the development of first/best-in-class cell therapy for cancer treatment.  

Leadership Team

  • Cao Zhuoxiao

    Cao Zhuoxiao

    M.D., Ph.D.

    CEO
  • Zou Chaozhong

    Zou Chaozhong

    Ph.D.

    CTO
  • Ye Gang

    Ye Gang

    M.D.

    Clinical VP
  • Dr. Wang Pin

    Dr. Wang Pin

    Tenured Prof. of USC

    Scientific Advisor
  • Dr. Tamas Oravecz

    Dr. Tamas Oravecz

    CSO, U.S. of Simcere

    Scientific Advisor

Our History

Our History
    • 2019
    • 2019

      Established in
      Cambridge MA,USA

    • 2020
    • 2020

      GMP facility completed in
      Shanghai

    • 2021
    • 2021

      Simnova spun off from
      Simcere to become an
      independent company

    • 2022
    • 2022

      The first product of the allogeneic CAR-NK platform has entered clinical stage

       

      The first product of double CAR-BiTE autologous CAR-T platform for solid tumor has entered clinical stage

       

      BCMA CAR-T program started clinical trial initiated